Sivia Capital Partners LLC Buys 13,598 Shares of Exelixis, Inc. $EXEL

Sivia Capital Partners LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 95.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 27,811 shares of the biotechnology company’s stock after purchasing an additional 13,598 shares during the period. Sivia Capital Partners LLC’s holdings in Exelixis were worth $1,219,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Farallon Capital Management LLC grew its holdings in Exelixis by 21.6% during the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock valued at $805,412,000 after purchasing an additional 3,466,000 shares during the period. AQR Capital Management LLC grew its holdings in Exelixis by 20.7% during the third quarter. AQR Capital Management LLC now owns 9,181,359 shares of the biotechnology company’s stock valued at $379,190,000 after purchasing an additional 1,575,280 shares during the period. Invesco Ltd. grew its holdings in Exelixis by 7.1% during the third quarter. Invesco Ltd. now owns 5,960,525 shares of the biotechnology company’s stock valued at $246,170,000 after purchasing an additional 394,897 shares during the period. Dimensional Fund Advisors LP grew its holdings in Exelixis by 11.2% during the third quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock valued at $172,658,000 after purchasing an additional 419,596 shares during the period. Finally, UBS Group AG grew its holdings in Exelixis by 40.2% during the fourth quarter. UBS Group AG now owns 3,722,334 shares of the biotechnology company’s stock valued at $163,150,000 after purchasing an additional 1,067,265 shares during the period. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 32,110 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total value of $1,599,399.10. Following the sale, the executive vice president directly owned 357,638 shares in the company, valued at approximately $17,813,948.78. The trade was a 8.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jack L. Wyszomierski sold 3,925 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $50.55, for a total value of $198,408.75. Following the completion of the sale, the director owned 284,384 shares in the company, valued at $14,375,611.20. This represents a 1.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 219,170 shares of company stock valued at $10,620,641 in the last ninety days. Company insiders own 2.60% of the company’s stock.

Exelixis Stock Up 6.3%

NASDAQ EXEL opened at $51.60 on Thursday. The firm has a market cap of $12.97 billion, a price-to-earnings ratio of 17.14, a price-to-earnings-growth ratio of 1.02 and a beta of 0.41. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $52.96. The business has a 50-day moving average price of $46.54 and a 200-day moving average price of $44.39.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. The company had revenue of $610.81 million for the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.55 earnings per share. Research analysts expect that Exelixis, Inc. will post 3.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EXEL. Wells Fargo & Company boosted their price objective on Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research note on Tuesday, May 19th. Morgan Stanley upped their price objective on Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $47.35.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.